Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

New products to underpin growth into 2024

Control Bionics
3:27pm
February 7, 2024
Following a successful A$2.7m rights issue, CBL is now funded into 2024 with new products (DROVE and NeuroStrip) adding to the improving sales position. Australia delivered solid revenue growth in 1H24 (despite NDIS delays) and momentum is expected to continue in 2H. However, sales in North America in 1H24 were flat although management expects an improvement in 2H. We are moving a number of our early stage development companies to the new ‘Keeping Stock’ format which enables us to continue to provide regular and timely updates. We will cease providing a rating, valuation and forecasts. Therefore, our previous forecasts, target price and recommendation should no longer be relied upon for investment decisions.

Remaining steady

Dexus Convenience Retail REIT
3:27pm
February 6, 2024
DXC’s 1H24 result delivered stable portfolio metrics with the focus during the half on maintaining balance sheet resilience. Gearing at c32%. Dec-23 revaluations saw cap rates expand 20bps (-1.7% portfolio impact). NTA stands at $3.63 vs $3.75 at Jun-23. FY24 guidance has been tightened slightly and now comprises FFO and DPS of 20.8-21.1c (was 20.7-21.1c). This equates to a distribution yield of approx. 8%. DXC remains an Add with a revised price target of $3.23.

More than a gut feeling

Microba Life Sciences
3:27pm
February 6, 2024
Microba Life Sciences (MAP) is an emerging leader in the microbiome industry specialising in gut health testing and therapeutic development. The company provides a comprehensive end-to-end solution, encompassing internally developed tests and therapeutic candidates generated via its discovery engine and artificial intelligence (AI) capabilities. In collaboration with renowned microbiome specialists worldwide, MAP stands out as a distinctive value proposition, offering high-margin products and opportunities through its therapeutics discovery platform. The expanding testing services business and increasing awareness among healthcare professionals about the pivotal role of the microbiome are driving a surge in demand. This heightened awareness is fueling increased interest in microbiome-related services, products, and advancements, indicating a growing recognition of its impact on overall health across diverse medical applications. We initiate coverage of MAP with a valuation and target price of A$0.35 p/s with a Speculative Buy recommendation.

Building towards the next earnings step-up

Pinnacle Investment Mgmt
3:27pm
February 2, 2024
Group NPAT was flat on the pcp at A$30.2m and in line with expectations. Affiliate NPAT contribution was +31% on pcp but -9% ex-performance fees. Group FUM closed at A$100.1bn, up 9% over the half. Starting 2H24 FUM is up ~8% on 1H24 average (flows and market uplift late in the half). 1H24 Net flows comprised: retail +A$1.8bn; domestic insto -A$0.4bn; and offshore +A$3.1bn. QoQ improvement was experienced (1Q A$0.2bn; 2Q A$4.3bn). PNI’s near-term valuation (~26x FY24 PE) sees the stock susceptible to short-term volatility. However, PNI has structural growth drivers and we see the medium-term (FY25/26) earnings step-up is supported by: a return to improved flows; higher performance fee FUM; significant operating leverage on improved FUM; leveraging the recent investment spend; and the eventual addition of new managers.

Executing its strategy

MoneyMe
3:27pm
February 1, 2024
MoneyMe (MME) has released a 1H24 trading update, which whilst brief, did highlight the continued execution of management’s strategy to improve the overall credit quality of the book itself (average Equifax score 741) and focus on profitability. The gross loan book remained stable at A$1.2bn, generating revenue of >A$105m (-~13% on pcp) and a statutory NPAT of A$6m. Our FY24F-FY26F EBITDA is lowered by ~3-9% on slight adjustments to gross loan book growth rates, loss rates and book yield. Our DCF/PB blended valuation (equal-weighted) and price target remains unchanged at A$0.25 on the above changes offset by timing impacts of our DCF.

Execution in the US required

Credit Corp
3:27pm
January 31, 2024
CCP’s 1H24 underlying NPAT of A$33.5m (+5% on pcp) missed consensus expectations (>15%) on higher lending provisioning; and high cost growth. CCP held NPAT guidance. The mid-point looks achievable (implied 2H24 NPAT ~A$51.5m), with 2H Lending volumes the main swing factor. Despite the ‘miss’, CCP’s FY25/26 earnings outlook remains largely unchanged. However, the composition skews further to Consumer Lending; and trust in the USA execution is required (only slight incremental US ‘evidence’ in this result). Backing management’s execution in delivering on USA divisional growth expectations over FY25/26 is needed. We think the valuation point (11.5x FY25PE) provides enough upside and risk/reward to do so. Add maintained.

Hitting its targets

Airtasker
3:27pm
January 31, 2024
Airtasker (ART) released a broadly positive 2Q24 trading update in our view, which saw an +8% increase in group revenue to A$12.2m, and the business achieving positive free cash flow for the period. We make upward revisions to our FY25-26F revenue estimates on an improved take-rate (details below). Our DCF/Multiples derived price target increases marginally to A$0.54 (from A$0.53). Add maintained.

Share price over reaction to an exciting outlook

ImpediMed
3:27pm
January 31, 2024
IPD share price has come under selling pressure after the release of its 2Q24 cashflow report which was below expectation. However we believe this is an overreaction with excellent progress being made with private payor coverage. IPD highlight that 13 states in the US have reached critical mass (ie 80% of population covered for reimbursement from private payors or Medicare). The target is that 85% of the US will be providing coverage by the end of FY24. Following a change in management estimates of revenue recognition to equal monthly payments across the term of each contract we have revised our revenue forecast. As a result our DCF based valuation has reduced to A$0.20 (was A$0.22). we maintain our Speculative Buy recommendation.

4Q23 report card

Atlas Arteria
3:27pm
January 30, 2024
The 4Q23 traffic and toll revenue data presented minimal surprises on the key roads that contribute to the bulk of ALX’s equity valuation. 12 month target price lifts 3 cps to $5.61, mostly driven by higher Chicago Skyway toll escalation for FY24 and FY25 than previously assumed. HOLD retained, albeit value does look attractive at current prices with c.10% potential TSR (underwritten by a c.7% cash yield).

Good progress on all fronts

Micro-X
3:27pm
January 30, 2024
MX1 posted its 2Q24 report which showed a net operating cash inflow of A$4.3m which was boosted by the receipt of a R&D rebate of A$6.2m. Pleasingly, Mobile DR receipts are ticking up and project work with the ASA and DHA remain on track. Our focus remains on turning customer and distributor demonstrations of the Argus into sales. At this stage we have made no changes to our forecasts, valuation or target price of A$0.27. We maintain a Speculative Buy recommendation.

News & Insights

Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more
Michael Knox outlines the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and his own analysis for Australia.

Today, I’m presenting the first page of my updated presentation, which focuses on GDP growth and inflation expectations for major economies. Before diving into that, I want to clarify a point about U.S. trade negotiations that has confused some media outlets.

In the previous Trump Administration ,there was single trade negotiator, Robert Lighthizer, held a cabinet position with the rank of Ambassador. This time, to expedite negotiations and give them more weight, Trump has appointed two additional cabinet-level officials to handle trade talks with different regions. For Asian economies, Scott Bessent and Ambassador Jamison Greer, who succeeded Lighthizer and previously served on the White House staff, are managing negotiations, including those with China. For Europe, Howard Lutnick, the Commerce Secretary, and Ambassador Greer are negotiating with the European Trade Representative. When the EU representative visits Washington, D.C., they meet with Lutnick and Greer, while Chinese or Japanese representatives engage with Bessent and Greer.

In my presentation today, I’m outlining the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and my own analysis for Australia.

For the U.S., the best-case scenario is a soft landing, with growth slowing but remaining positive at 1.3% this year and rising to 1.7% next year. This slowdown allows the Federal Reserve to continue cutting interest rates, leading to a decline in the U.S. dollar. This in turn ,triggers a recovery in commodity prices. These prices have stabilized and are now trending upward, with an expected acceleration as the dollar weakens.

U.S. headline inflation is projected to be just below 3% next year, with higher figures this year driven by tariff effects.



Global Economic Perspective

In the Euro area, growth is accelerating slightly, from just under 1% this year to 1.2% next year, with inflation expected to hit the 2% target this year and dip to 1.9% next year.

China’s GDP growth is forecast  at 4% for both this year and next, a step down from previous 5% rates, reflecting a significant slump in domestic demand and very low inflation  Chinese Inflation is only  :   0.2% last year, 0.4% this year, and 0.9% next year.  Despite a massive fiscal push, with a budget deficit around 8% of GDP, China’s debt-to-GDP ratio is rising faster than the U.S.. Yet this is  yielding more modest  domestic growth.

India, on the other hand, continues to outperform, with 6.5% GDP growth last year, 6.2% this year, and  6.3%  next year, surpassing earlier projections.

Read more
In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia.

Positive earnings surprise

In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia. For all the volatility in markets caused by US trade policy, the results were positive. For all the 187 high profile and blue-chip companies in our International Watchlist, the median EPS beat vs consensus was 3.2%, nearly twice that recorded in the December quarter (1.8%). 37% of companies exceeded consensus EPS expectations by more than 5% and only 9% missed by more than 5%. Communication Services was the most positive sector, led by Magnificent 7 companies Alphabet and Meta Platforms. The median EPS beat in that sector was 13%. Consumer Discretionary was the biggest disappointment (though only a mild one) with EPS falling 0.6% short of analyst estimates on a median basis.

Alphabet and Meta among the best performers

Across our Watchlist, some of the best performing stocks in terms of EPS beats were Alphabet, Boeing, Uniqlo-owner Fast Retailing, Meta Platforms, Newmont and The Walt Disney Company. Notable misses came from insurance broker Aon, BP, PepsiCo, Starbucks, Tesla and UnitedHealth. The latter saw by far the worst share price performance over reporting season, its earnings weakness compounded by the resignation of its CEO and the launch of a fraud investigation by the Department of Justice. British luxury fashion label Burberry had the best performing share price as it gains traction in its turnaround plan.

Tariffs were the main talking point (of course)

The timing of President Trump’s ‘Liberation Day’ on 2 April, just before the March quarter results started rolling in, guaranteed that US tariffs would be the main talking point throughout reporting season. Most companies took the line that higher tariffs presented a material risk to global growth and inflation. The rapidly shifting sands of US trade policy mean the impact of tariffs is highly uncertain. This didn’t stop many companies from trying to estimate the impact on their profits. This ranged from the very precise ($850m said RTX) to the extremely vague (‘a few hundred million dollars’ hazarded Abbott Laboratories). The rehabilitation of AI as a systemic driver of long-term value was a key theme of reporting season, with many companies reporting what Palantir Technologies described as an ‘unstoppable whirlwind of demand’ and others indicating an increase in planned AI investment. The deterioration in consumer confidence was another key talking point, though most companies could only express concern about a possible future softening in demand rather than any actual evidence of a hit to sales.

Our International Focus List continues to outperform

In this report, we also report on the performance of the Morgans International Focus List, which is now up 25.3% since inception last year, outperforming the benchmark S&P 500 by 20.4%.


Morgans clients receive exclusive insights such as access to our latest International Reporting Season article.

Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more